Detalhe da pesquisa
1.
PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy.
BJU Int
; 133(4): 425-431, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37916303
2.
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
Oncologist
; 28(4): 333-340, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36576173
3.
Targeting HIF-2 Alpha in Renal Cell Carcinoma.
Curr Treat Options Oncol
; 24(9): 1183-1198, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37403008
4.
Studying the association between breast cancer and renal cell carcinoma.
Breast Cancer Res Treat
; 191(3): 643-652, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34855061
5.
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Lancet Oncol
; 20(10): 1386-1394, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31427205
6.
Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Prostate
; 78(13): 1035-1041, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29882332
7.
The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma.
Br J Cancer
; 119(2): 160-163, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29795307
8.
Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia.
Am J Hematol
; 89(2): 168-73, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24123154
9.
Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma.
Clin Genitourin Cancer
; 22(2): 92-97, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37932205
10.
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
Clin Genitourin Cancer
; 22(2): 368-379, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38245437
11.
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
J Immunother Cancer
; 12(4)2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38604810
12.
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
J Immunother Cancer
; 11(3)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36948504
13.
Clinical Review on the Management of Metastatic Renal Cell Carcinoma.
JCO Oncol Pract
; 18(3): 187-196, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529499
14.
Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate.
Eur Urol Focus
; 8(6): 1575-1582, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35662504
15.
Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors.
Target Oncol
; 17(5): 563-569, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35986816
16.
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma.
Eur Urol
; 81(6): 555-558, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34980496
17.
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
J Clin Oncol
; 40(25): 2913-2923, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35442713
18.
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
J Immunother Cancer
; 10(10)2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36252996
19.
Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma.
Curr Oncol
; 28(6): 5019-5024, 2021 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34940060
20.
Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis.
J Immunother Cancer
; 9(10)2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34599022